Physician
Hematology
Dr. David R. Fogelman, MD
|
|
Give Review
David Fogelman works in the field of Hematology. He went to medical school at Albert Einstein College of Medicine. Dr. David R. Fogelman is a published doctor. He has 27 papers published. The most current publication "Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer." He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Retrospective Analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction.
- Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.
- Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
- Perfusion Computed Tomography as Functional Biomarker in Randomized Run-In Study of Bevacizumab and Everolimus in Well-Differentiated Neuroendocrine Tumors.
- Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer.
- Role of Neoadjuvant Therapy in the Multimodality Treatment of Older Patients with Pancreatic Cancer.
- Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic Cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of ge...
- Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic Cancer?
- Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?: A Pooled Analysis of Phase II Trials of Gemcitabine-Containing...
- The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic Cancer.
- Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic AdenoCarcinoma Treated with Neoadjuvant Therapy.
- The use of GTX as second-line and later chemotherapy for metastatic pancreatic Cancer: a retrospective analysis.
- Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.
- Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer.
- The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic Cancer: from 5-fluorouracil to GTX.
- Clinician safety.
- Salmonella enterica serotype Dublin infection: an emerging infectious disease for the northeastern United States.
- Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic Cancer: a phase II trial.
- Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic coloRectal metastases.
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic Cancer: results of two phase II studies.
- Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenoCarcinoma.
- Aggressive combined modality therapy for recurrent colorectal Cancer involving the duodenum and pancreas: a report of 5 cases.
- The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic Cancer: a retrospective analysis.
- Androgen and c-Kit receptors in desmoplastic small round Cell tumors resistant to chemotherapy: novel targets for therapy.
- Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic Cancer.
- Emerging drugs for colorectal Cancer.
Schools
A Einstein Col Med Yeshiva Univ
A Einstein College M Yeshiva University
Ny and Presby Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Golden Rule
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Old Surety Life Insurance CompanyMedicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
New York Presbyterian Hospital -
Albert Einstein College of Medicine -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1811918634 | |
| NPPES Provider LastName | FOGELMAN | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 770304000 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 317.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 4.1 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1811918634 |
| Last Name Of The Provider | FOGELMAN |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Cristina Rodriguez, MD |
|
|
Dr. Anita Sabichi, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Steven M. Kornblau, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Carlos E. Bueso-Ramos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Caroline C. Waddell, MD |
|
|
Dr. John T. French, MD |
|
|
Dr. Aaron J. Schueneman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
David T. Kang |